심방세동 치료제 시장 : 제품 유형, 용도, 최종사용자, 지역별(2024-2031년)

Atrial Fibrillation Drugs Market Valuation - 2024-2031

Rising rates of lifestyle-related risk factors such as obesity and hypertension among the growing population, especially geriatric populace, is bolstering the demand for early detection and treatment, creating immense opportunities for Atrial Fibrillation Drugs Market. According to the analyst from Verified Market Research, the Atrial Fibrillation Drugs Market is estimated to reach a valuation of USD 19.91 Billion over the forecast subjugating aroundUSD 14.78 Billion valued in 2023.

Ongoing research efforts focusing on novel therapeutic techniques, such as the development of anti-arrhythmic medicines, anticoagulants, and rate control pharmaceuticals, are further increasing Atrial Fibrillation Drugs Market expansion and enabling the market to grow at aCAGR of 3.8% from 2024 to 2031.

Atrial Fibrillation Drugs Market: Definition/ Overview

Atrial fibrillation drugs are medications that are specifically intended to manage and treat atrial fibrillation, a common heart rhythm disease characterized by irregular and fast heartbeats that originate in the heart's upper chambers (atria). These medications perform a variety of functions in the treatment of atrial fibrillation, including restoring normal heart rhythm (sinus rhythm), managing heart rate, and lowering the risk of blood clots and stroke.

Furthermore, anti-arrhythmic drugs are commonly prescribed to assist restore a regular heart rhythm, whereas rate control medications try to keep the heart rate within normal limits. Also, anticoagulant drugs are often prescribed to prevent blood clot development and lower the risk of stroke, as people with atrial fibrillation have a higher risk of blood clots due to their irregular heartbeat.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will High Prevalence of Chronic Illnesses Affect the Atrial Fibrillation Drugs Market?

The growing prevalence of atrial fibrillation around the world is a significant driver of the market. Atrial fibrillation is the most frequent type of severe arrhythmia, affecting millions of people globally, increasing the need for new treatment alternatives. Ageing populations, as AFib incidence rises with age, as well as rising rates of underlying diseases such as hypertension, diabetes, and obesity, all contribute to rising prevalence.

Increased global healthcare spending, particularly in developed and emerging economies, contributes to the expansion of the Atrial Fibrillation Drugs Market. With healthcare systems prioritizing quality care and outcomes, there is a greater emphasis on the effective management of chronic illnesses such as atrial fibrillation This involves the use of innovative treatment alternatives, which can improve patient outcomes and lower long-term healthcare expenditures.

Furthermore, early identification and treatment of atrial fibrillation are becoming increasingly important in preventing consequences such as stroke and heart failure. Early detection through the widespread use of wearable technology and mobile health apps that can monitor cardiac rhythms and identify anomalies also helps to drive market expansion. These initiatives increase the number of people diagnosed with atrial fibrillation, which broadens the patient pool that requires drug therapy.

What will Side Effects of Atrial Fibrillation Drugs have on the Market?

Many drugs used to treat atrial fibrillation, particularly anticoagulants, are associated with substantial side effects, such as bleeding problems. These safety concerns limit the use of specific medications in particular patients cause healthcare practitioners and patients to be hesitant about managing atrial fibrillation pharmacologically, and limiting market growth.

The expiration of patents for important medications in the atrial fibrillation market allows for generic competition, substantially decreasing revenue for pharmaceutical companies that produced the original branded drugs. While generics make drugs more affordable, they also pose a challenge to the market by reducing incentives for innovation and investment in new medication research.

Furthermore, despite the global prevalence of atrial fibrillation, many emerging economies still have limited access to modern treatment options, including the most recent anticoagulants, due to high costs, a lack of healthcare infrastructure, and a lack of awareness among healthcare providers and patients. This difficulty is exacerbated by socioeconomic reasons and differences in healthcare systems, which impede the expansion of the atrial fibrillation medication market in these locations.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for the Anticoagulant segment?

According to VMR analysis, the anticoagulant drugs segment is estimated to hold the largest market share during the forecast period. The global growth in atrial fibrillation prevalence has led to an increase in the demand for better stroke prevention methods. Anticoagulant medications, particularly NOACs, are the cornerstone of stroke prevention in atrial fibrillation patients, which contributes to their market dominance. The emphasis on lowering the risk of stroke in atrial fibrillation patients with appropriate anticoagulant medication contributes to the segment's sustained expansion and dominance.

Novel Oral Anticoagulants (NOACs) have been proven to be as effective as or more effective than Vitamin K Antagonists (VKAs) such as warfarin, with a better safety profile, particularly in terms of lowering the risk of significant bleeding problems. NOACs also have less food-drug interactions than VKAs, making them a more convenient choice for patients. This increased efficacy and safety profile has resulted in a high preference for NOACs among healthcare providers and patients, contributing to the anticoagulant drug segment's dominance.

Furthermore, clinical recommendations from top cardiology and thrombosis associations throughout the world increasingly advocate NOACs over VKAs for the majority of AFib patients due to their favorable benefit-risk profile. These guidelines have an impact on prescribing practices and have played a crucial role in the broad adoption of NOAC. The robust endorsement by clinical guidelines assures that NOACs continue their leading position in the anticoagulant drug market.

What are the Potential Factors for the Dominance of Paroxysmal Type in the Market?

The paroxysmal segment is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. Paroxysmal Atrial Fibrillation, which is characterized by the abrupt start of irregular heartbeats that stop within seven days (typically resolving within 24 hours), is common since it is frequently the first phase of atrial fibrillation in many people. Drugs aimed at this segment are in more demand because of their episodic character, which often makes it the first kind of atrial fibrillation to be recognized and treated.

Paroxysmal atrial fibrillation is generally treated with a combination of medicines, ranging from anticoagulants to prevent strokes to antiarrhythmic drugs to regulate rhythm. This variety of treatment alternatives can help the segment get a greater market share because it includes a wide range of pharmaceuticals that can be adapted to particular patient needs, as well as newer and more advanced pharmacological breakthroughs.

Furthermore, effectively managing paroxysmal atrial fibrillation can stop or slow the development of more chronic and persistent forms of the condition, which are more difficult to treat and have a higher risk of problems. This therapeutic potential supports a high emphasis on early and effective treatment techniques, including medication therapies, which contributes to the segment's dominance in the Atrial Fibrillation Drugs Market.

Country/Region-wise Acumens

What are the Factors that Contribute to North America's Competitive Edge in the Market?

According to VMR analyst, North America is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. North America, particularly the United States, has a high frequency of cardiovascular disorders, including atrial fibrillation, which is caused by variables such as ageing populations, lifestyle choices, and obesity. This results in a large patient pool requiring atrial fibrillation treatment, which fuels demand for atrial fibrillation drugs.

The region has advanced healthcare systems that provide extensive access to cutting-edge medical technology and treatments. This infrastructure promotes early diagnosis, treatment innovation, and successful management of atrial fibrillation, resulting in higher acceptance rates of innovative atrial fibrillation medications than other locations.

Furthermore, North America is a pharmaceutical research and development hotspot, with a significant emphasis on innovative drug therapies. The presence of major pharmaceutical companies, as well as significant investment in R&D activities, help to accelerate the release of novel and effective atrial fibrillation medications, boosting market expansion in the region.

Will Flourishing Healthcare Infrastructure in Asia Pacific Boom Atrial Fibrillation Drugs Market?

Asia Pacific region is estimated to exhibit the highest growth in the market during the forecast period. Asia Pacific is experiencing a substantial demographic shift, with increasing ageing populations, particularly in Japan and China. Older age is a significant risk factor for atrial fibrillation, resulting in an increasing patient population in need of atrial fibrillation treatments and driving demand for atrial fibrillation medications in the region.

This region is experiencing significant advances in healthcare infrastructure and increased healthcare spending. Countries are investing in better healthcare infrastructure and treatment access, making modern atrial fibrillation medications more accessible to the general public, hence driving market expansion.

Furthermore, in the Asia-Pacific region, there is growing awareness of atrial fibrillation and associated complications. When combined with increased healthcare access and insurance coverage, this leads to higher diagnostic rates and treatment uptake, driving the expansion of the Atrial Fibrillation Drugs Market.

Competitive Landscape

The competitive landscape of the Atrial Fibrillation Drugs Market is marked by fierce competition among several players vying for a significant market share. In addition, market participants frequently pursue strategic partnerships, collaborations, and acquisitions to boost their market position and broaden their product ranges.

Some of the prominent players operating in the Atrial Fibrillation Drugs Market include:

Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc., Novartis AG, Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Medtronic plc, Shionogi & Co., Ltd., Astellas Pharma Inc., Meda Pharmaceuticals, and Cardionomic Therapeutics Inc.

Latest Developments

In October 2023, Bristol-Myers Squibb announced favorable findings from the Phase 3 PEACH-AF trial. The experiment assessed the efficacy and safety of the investigational medication, lixisenatide, in preventing stroke in individuals with AF.

In September 2023, Pfizer Inc. announced a collaboration with Apple to create a new wearable device that can detect and monitor AF via a person's smartphone.

In April 2023, Johnson & Johnson presented results at the American College of Cardiology meeting that demonstrated the long-term safety and efficacy of their medicine, Edoxaban, in avoiding stroke in patients with AF.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ATRIAL FIBRILLATION DRUGS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antiarrhythmic Drug
• 5.3 Anticoagulant Drugs
  • 5.3.1 Vitamin K Antagonists
  • 5.3.2 Novel Oral Anticoagulants

6 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY TYPE

• 6.1 Overview
• 6.2 Paroxysmal
• 6.3 Persistent
• 6.4 Permanent

7 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Heart Rhythm Control
• 7.3 Heart Rate Control

8 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY END USER

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Cardiac Centers
• 8.4 Ambulatory Surgical Centers

9 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe & Africa
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Bristol-Myers Squibb
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Johnson & Johnson
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Pfizer Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Novartis AG
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 F. Hoffmann-La Roche Ltd
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Sanofi S.A.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Merck & Co., Inc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11. 9 Daiichi Sankyo Company, Limited
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Boehringer Ingelheim GmbH
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research